Fresenius SE & Co KGaA (FRE) Given a €61.00 Price Target by Goldman Sachs Group Analysts

Goldman Sachs Group set a €61.00 ($70.93) target price on Fresenius SE & Co KGaA (FRA:FRE) in a research report report published on Monday. The firm currently has a neutral rating on the stock.

Several other research firms have also recently issued reports on FRE. UBS Group set a €57.00 ($66.28) price objective on Fresenius SE & Co KGaA and gave the stock a sell rating in a report on Monday, August 6th. DZ Bank restated a buy rating on shares of Fresenius SE & Co KGaA in a report on Tuesday, August 7th. Deutsche Bank set a €82.00 ($95.35) target price on Fresenius SE & Co KGaA and gave the stock a buy rating in a research report on Thursday, July 19th. Warburg Research set a €80.00 ($93.02) target price on Fresenius SE & Co KGaA and gave the stock a buy rating in a research report on Thursday, October 4th. Finally, Sanford C. Bernstein set a €83.00 ($96.51) target price on Fresenius SE & Co KGaA and gave the stock a buy rating in a research report on Monday, July 9th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and fourteen have given a buy rating to the company. Fresenius SE & Co KGaA has a consensus rating of Buy and a consensus price target of €75.52 ($87.81).

Shares of FRA:FRE opened at €54.04 ($62.84) on Monday. Fresenius SE & Co KGaA has a one year low of €60.16 ($69.95) and a one year high of €80.00 ($93.02).

Fresenius SE & Co KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

See Also: Do You Need a Fiduciary?

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply